分组1 - Select Medical (SEM) shares have increased by 2.5% over the past four weeks, closing at $13.37, with a mean price target of $18.17 indicating a potential upside of 35.9% [1] - The mean estimate consists of six short-term price targets with a standard deviation of $2.64, where the lowest estimate is $14.00 (4.7% increase) and the highest is $21.00 (57.1% increase) [2] - Analysts show strong agreement in revising SEM's earnings estimates higher, which correlates with potential stock price increases [11][12] 分组2 - The Zacks Consensus Estimate for SEM has risen by 4.5% over the past month, with two estimates increasing and no negative revisions [12] - SEM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Core Insights - Select Medical Holdings Corporation (SEM) is a key player in the healthcare sector, focusing on critical illness recovery, inpatient rehabilitation, and outpatient therapy, with a network of hospitals and clinics across the U.S. [1] - SEM has demonstrated resilience with a 30-day gain of 3.15%, although it experienced a slight decline of 2.82% over the last 10 days, which may present a strategic entry point for investors [2] - Analysts estimate a significant upside of 26.68% for SEM, with a target price set at $17, indicating strong growth potential [3] - The company has a robust financial standing, evidenced by a Piotroski Score of 8, highlighting its strong fundamentals in profitability, leverage, liquidity, and operating efficiency [4] - Overall, SEM represents a compelling investment opportunity due to its strong financial metrics and recent stock price dip, making it attractive for long-term growth [5] Performance Analysis - SEM's recent performance includes a 30-day gain of 3.15% and a 10-day decline of 2.82%, suggesting volatility but also potential for recovery [2][6] Growth Potential - The estimated upside for SEM is 26.68%, with a target price of $17, reflecting analysts' confidence in the stock's appreciation potential [3][6] Financial Health - SEM's Piotroski Score of 8 indicates solid financial fundamentals, positioning the company well for sustained growth and stability in the competitive healthcare market [4][6]

Financial Data and Key Metrics Changes - Revenue grew over 7% to $1.36 billion, compared to $1.27 billion in the prior year [7] - Adjusted EBITDA increased over 7% to $111.7 million, up from $103.9 million [7] - Earnings per common share from continuing operations rose over 21% to $0.23, compared to $0.19 per share in the same quarter last year [7] - Cash flow from operating activities was $175.3 million [10] Business Line Data and Key Metrics Changes - Inpatient rehabilitation hospital division revenue increased 16% year-over-year to $328.6 million, with adjusted EBITDA up 13% to $68 million [7] - Outpatient rehabilitation division revenue increased 4% to $325.4 million, driven by over 5% growth in patient visits, but net revenue per visit decreased to $100 from $101 [8] - Critical illness recovery hospital division revenue increased over 4% to $609.9 million, with adjusted EBITDA rising over 10% to $56.1 million [8] Market Data and Key Metrics Changes - Average daily census rose 11% in the inpatient rehabilitation segment, with occupancy improving to 83% from 82% [8] - Same-store occupancy in inpatient rehabilitation rose to 86% from 85% [8] - Occupancy in the critical illness recovery hospital division remained steady at 65%, with admissions up 2.1% [9] Company Strategy and Development Direction - The company plans to add 395 inpatient rehabilitation beds by 2027 through new openings and strategic bed additions [5] - Future development efforts will focus on the inpatient rehabilitation segment, with several new hospitals planned [6] - The company is committed to enhancing shareholder value through cash dividends and share repurchase [6] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the delay of the 20% transmittal rule, expecting it to have less impact due to stabilized labor costs [4] - The company reaffirmed its business outlook for 2025, expecting revenue between $5.3 billion and $5.5 billion and adjusted EBITDA between $510 million and $530 million [11] - Management noted ongoing challenges with high-cost outlier thresholds affecting admissions and occupancy in the LTAC business [16][20] Other Important Information - The company acquired a 30-bed critical illness recovery hospital in Memphis and opened three new outpatient clinics during the quarter [4] - A cash dividend of $0.0625 per share was approved, payable on November 25, 2025 [6] Q&A Session Summary Question: Impact of the high-cost outlier on admission volume and occupancy - Management noted that the increasing fixed loss threshold negatively impacts the LTAC business, affecting the ability to accommodate acutely ill patients [16][17] Question: Discussions with CMS regarding payment increases - Management indicated that there are many levers in the reimbursement system, and they are advocating for various options to help the industry [24][25] Question: Revenue benefit from the delay of the 20% transmittal rule - The net impact was estimated to be in the $12 million to $15 million range for the quarter [31] Question: Softness in the outpatient segment - Management attributed the softness to a reduction in Medicare reimbursement and a shift in payer mix [37][48] Question: Future headwinds and tailwinds for 2026 - Management expects a modest increase in Medicare rates, which could serve as a tailwind, while the return of the 20% transmittal rule will be a headwind [39] Question: Development pipeline and startup costs - Management projected approximately $15 to $20 million of startup losses per annum, consistent with previous years [59] Question: Labor cost trends - The labor environment is more stable, with agency rates returning to pre-COVID levels and full-time equivalent costs increasing slightly [61] Question: Leverage and capital allocation - Management indicated that a net leverage of 3.4 times is comfortable, with capital allocation focused on development, dividends, and opportunistic debt reduction [63]

Core Insights - Select Medical (SEM) reported quarterly earnings of $0.23 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, but down from $0.5 per share a year ago, representing an earnings surprise of +27.78% [1] - The company posted revenues of $1.36 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.87%, but down from $1.76 billion year-over-year [2] - Select Medical shares have declined approximately 24.2% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $1.36 billion, and for the current fiscal year, it is $1.18 on revenues of $5.38 billion [7] - The estimate revisions trend for Select Medical was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - HMOs industry, to which Select Medical belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Humana (HUM), another company in the same industry, is expected to report quarterly earnings of $2.91 per share, reflecting a year-over-year decline of -30.1%, with revenues anticipated to be $31.98 billion, up 9.1% from the previous year [9][10]

Revenue Performance - Revenue for Q3 2025 increased 7.2% to $1,363.4 million compared to $1,271.6 million in Q3 2024[3] - For the nine months ended September 30, 2025, revenue increased 4.7% to $4,056.2 million compared to $3,874.5 million in the same period of 2024[4] - The rehabilitation hospital segment saw a revenue increase of 16.2% to $328.6 million in Q3 2025 compared to $282.7 million in Q3 2024[9] - The outpatient rehabilitation segment's revenue increased 3.2% to $960.3 million for the nine months ended September 30, 2025, compared to $930.7 million in the same period of 2024[12] - Total revenue for Q3 2025 increased to $609,929, a 4.6% rise from $582,950 in Q3 2024[33] - Total revenue for the nine months ended September 30, 2025 was $1,848,098, a slight increase of 0.2% from $1,843,751 in 2024[34] Income and Earnings - Income from continuing operations before other income and expense rose 32.9% to $73.0 million for Q3 2025, up from $54.9 million in Q3 2024[3] - Net income attributable to Select Medical decreased by 48.2% to $28,793 in Q3 2025 from $55,628 in Q3 2024[24] - Income from continuing operations before income taxes rose by 22.5% to $55,929 in Q3 2025, up from $45,650 in Q3 2024[24] - Earnings per share for continuing operations increased to $0.23 in Q3 2025 from $0.19 in Q3 2024[29] - Net income for Q3 2025 decreased to $44,180, down 45.5% from $81,015 in Q3 2024[31] - Adjusted income from continuing operations, net of tax, attributable to common shares for Q3 2024 was $32,151,000, compared to $28,087,000 in Q3 2025, reflecting a decrease of 12.5%[42] Adjusted EBITDA - Adjusted EBITDA for Q3 2025 increased 7.5% to $111.7 million compared to $103.9 million in Q3 2024[3] - Adjusted EBITDA for Q3 2025 rose to $56,102, reflecting a 10.5% increase compared to $50,763 in Q3 2024[33] - The Adjusted EBITDA margin for the critical illness recovery hospital segment was 10.8% for the nine months ended September 30, 2025, down from 12.9% in the same period of 2024[8] - Select Medical's rehabilitation hospital segment generated $60,117,000 in Adjusted EBITDA for Q3 2024, increasing to $67,956,000 in Q3 2025, a growth of 13.0%[38] - Full year 2025 Adjusted EBITDA is projected to range between $510,000,000 and $530,000,000[46] Cash Flow and Expenses - Cash provided by operating activities for the nine months ended September 30, 2025 was $282,142, down 28.2% from $392,432 in the same period of 2024[32] - General and administrative expenses decreased by 25.4% to $108,721 for the nine months ended September 30, 2025, compared to $145,672 in 2024[26] - Cash paid for interest during the nine months ended September 30, 2025 was $84,002, down 61.2% from $216,757 in 2024[32] - Interest expense for Q3 2024 was $31,379,000, slightly decreasing to $30,021,000 in Q3 2025[38] Shareholder Returns and Stock Activity - The Board of Directors declared a cash dividend of $0.0625 per share, payable on or about November 25, 2025[13] - Select Medical repurchased 6,375,512 shares at a cost of approximately $96.5 million during the nine months ended September 30, 2025[16] Balance Sheet - Total assets increased to $5,685,723 as of September 30, 2025, compared to $5,607,951 at the end of 2024[30] - Total liabilities rose to $3,665,867 as of September 30, 2025, up from $3,610,856 at the end of 2024[30] Operational Metrics - Number of hospitals operated at the end of Q3 2025 was 105, a decrease from 106 in Q3 2024[33] - Revenue per patient day for Q3 2025 increased to $2,287, a 6.6% increase from $2,145 in Q3 2024[33] - Number of admissions in Q3 2025 increased to 8,859, a 2.1% rise from 8,676 in Q3 2024[33] - The number of patients admitted to Select Medical's hospitals during the periods presented is a critical metric for assessing operational performance[35] - The occupancy rate of hospitals is calculated using the number of patient days divided by total bed days available, indicating utilization levels[35] - Average revenue per patient day for the periods presented is calculated by dividing patient service revenues by total patient days, highlighting operational efficiency[35] Tax and Debt - Income tax expense from continuing operations increased by 168.6% to $11,749 in Q3 2025 from $4,374 in Q3 2024[24] - The company reported a loss on early retirement of debt amounting to $10,939 in both the three and nine months ended September 30, 2024[26] - The company reported a loss on early retirement of debt amounting to $10,939,000 for the nine months ended September 30, 2024[38]

Revenue Performance - The company reported revenue of $4,056.2 million for the nine months ended September 30, 2025, with approximately 46% from the critical illness recovery hospital segment, 23% from the rehabilitation hospital segment, and 24% from the outpatient rehabilitation segment[78]. - Total revenue for the nine months ended September 30, 2025, was $4,056.2 million, a 4.7% increase compared to $3,874.5 million for the same period in 2024[86]. - Revenue for the three months ended September 30, 2025, was $1,363.4 million, a 7.2% increase from $1,271.6 million in the same period of 2024[121]. - Revenue from the Critical Illness Recovery Hospital segment increased by 0.2%, while the Rehabilitation Hospital segment saw a 16.4% increase[87]. - Critical Illness Recovery Hospital segment revenue increased 4.6% to $609.9 million for the three months ended September 30, 2025, driven by a 6.6% increase in revenue per patient day to $2,287[122]. - Rehabilitation Hospital segment revenue rose 16.2% to $328.6 million, with patient days increasing 11.1% to 129,787 for the three months ended September 30, 2025[123]. - Outpatient Rehabilitation segment revenue increased 4.3% to $325.4 million, with patient visits up 5.5% to 2,924,794 for the three months ended September 30, 2025[124]. - Revenue for the Rehabilitation Hospital Segment increased by 16.4% to $949.8 million for the nine months ended September 30, 2025, compared to $816.2 million for the same period in 2024[139]. - Revenue for the Outpatient Rehabilitation Segment increased by 3.2% to $960.3 million for the nine months ended September 30, 2025, compared to $930.7 million for the same period in 2024[140]. Income and Profitability - For the three months ended September 30, 2025, income from continuing operations, net of tax, was $44.2 million, compared to $41.3 million for the same period in 2024, representing a growth of 7.0%[84]. - Income from continuing operations, net of tax, was $176.8 million for the nine months ended September 30, 2025, compared to $140.4 million for the same period in 2024[86]. - The company experienced a 10.1% increase in total income from continuing operations before other income and expenses[87]. - Net income for the three months ended September 30, 2025, was $43.6 million, down from $80.0 million in the same period of 2024[121]. Adjusted EBITDA - Adjusted EBITDA for the three months ended September 30, 2025, was $111.7 million, an increase of 7.5% compared to $103.9 million for the same period in 2024[84]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $388.5 million, with an adjusted EBITDA margin of 9.6%[86]. - Adjusted EBITDA for the Critical Illness Recovery Hospital Segment increased by 10.5% to $56.1 million for the three months ended September 30, 2025, compared to $50.8 million for the same period in 2024[127]. - Adjusted EBITDA for the Rehabilitation Hospital Segment increased by 13.0% to $68.0 million for the three months ended September 30, 2025, compared to $60.1 million for the same period in 2024[128]. - Adjusted EBITDA for the Outpatient Rehabilitation Segment decreased to $24.2 million for the three months ended September 30, 2025, down from $28.3 million for the same period in 2024[129]. - The Adjusted EBITDA margin for the total operations was 8.2% for the three months ended September 30, 2025[84]. - Adjusted EBITDA margin for the Critical Illness Recovery Hospital Segment was 9.2% for the three months ended September 30, 2025, compared to 8.7% for the same period in 2024[127]. Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $1,256.0 million, or 92.1% of revenue, down from 93.0% in the same period of 2024[125]. - Cost of services for the three months ended September 30, 2025, was $1,216.0 million, or 89.2% of revenue, compared to 89.3% in the prior year[125]. - General and administrative expenses decreased to $40.1 million, or 2.9% of revenue, from $47.3 million, or 3.7% of revenue, in the same period of 2024[125]. - Operating expenses were $3,681.5 million, or 90.8% of revenue, for the nine months ended September 30, 2025, compared to $3,524.0 million, or 91.0% of revenue, for the same period in 2024[141]. Cash Flow and Financing - Cash flows from operating activities provided $282.1 million for the nine months ended September 30, 2025, compared to $392.4 million for the same period in 2024[154]. - Investing activities used $149.6 million of cash flows for the nine months ended September 30, 2025, primarily for the purchase of property and equipment[156]. - Financing activities used $132.2 million of cash flows for the nine months ended September 30, 2025, with principal uses including $99.5 million for stock repurchases and $23.7 million in dividend payments[157]. - Cash and cash equivalents were $60.1 million as of September 30, 2025, with $419.1 million available under revolving facilities[162]. - The Board of Directors authorized a stock repurchase program of up to $1.0 billion, with 6,375,512 shares repurchased at a cost of approximately $96.5 million during the nine months ended September 30, 2025[160]. Market and Regulatory Environment - The company anticipates potential risks including changes in government reimbursement policies and economic conditions that could impact revenue and profitability[73]. - Medicare program revenue represented approximately 29% of total revenue for both the nine months ended September 30, 2025, and the year ended December 31, 2024[89]. - The standard federal rate for fiscal year 2026 is set at $50,825, an increase from $49,383 in fiscal year 2025[98]. - The fixed-loss amount for high-cost outlier cases under LTCH-PPS for fiscal year 2026 is $78,936, up from $77,048 in fiscal year 2025[98]. - The One Big Beautiful Bill Act is projected to reduce federal funding for Medicaid and CHIP by approximately $1 trillion over the next 10 years, impacting healthcare providers[93]. Future Plans and Initiatives - The company intends to pursue new joint venture relationships and open new outpatient rehabilitation clinics to drive incremental growth[161]. - An interest rate cap was entered into effective March 31, 2025, limiting the Term SOFR rate to 4.5% on $1.0 billion of principal outstanding under the term loan[170]. - A 0.25% increase in market interest rates will impact annual interest expense on variable rate debt by $3.0 million for the first increase, with subsequent increases being partially mitigated by the interest rate cap[171].

Core Viewpoint - Select Medical (SEM) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - For Select Medical, the Zacks Consensus Estimate has increased by 4.1% over the past three months, with expected earnings of $1.19 per share for the fiscal year ending December 2025, showing no year-over-year change [8]. Investment Implications - The upgrade reflects an improvement in Select Medical's underlying business, suggesting that investor sentiment may drive the stock price higher [5][10]. - The Zacks Rank system classifies stocks into five groups, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10].

Core Viewpoint - Select Medical (SEM) shares have increased by 7.8% in the past four weeks, closing at $13.19, with a mean price target of $18 indicating a potential upside of 36.5% [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.9, where the lowest estimate is $14.00 (6.1% increase) and the highest is $21.00 (59.2% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about SEM's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.1%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - SEM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for potential price movement [14]

Core Insights - Select Medical Holdings experienced a significant stock price increase of approximately 14% during morning trading on Wednesday, marking its best intraday gain in over five years [2] - The trading volume exceeded 1 million shares, indicating heightened investor interest and activity in the stock [2]

Core Points - Select Medical Holdings Corporation will release its financial results for the third quarter ended September 30, 2025, on October 30, 2025, after market close [1] - A conference call to discuss the third quarter results and business outlook is scheduled for October 31, 2025, at 9:00 am ET, which will be available via live webcast [2] - Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States, with operations in 40 states and the District of Columbia as of June 30, 2025 [4] Company Overview - As of June 30, 2025, Select Medical operated 104 critical illness recovery hospitals in 29 states, 36 rehabilitation hospitals in 14 states, and 1,919 outpatient rehabilitation clinics in 39 states and the District of Columbia [4] - The company’s reportable segments include critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation [4]